...
首页> 外文期刊>Journal of Controlled Release: Official Journal of the Controlled Release Society >Reversal of multidrug resistance phenotype in human breast cancer cells using doxorubicin-liposome-microbubble complexes assisted by ultrasound
【24h】

Reversal of multidrug resistance phenotype in human breast cancer cells using doxorubicin-liposome-microbubble complexes assisted by ultrasound

机译:阿霉素-脂质体-微泡复合物在超声辅助下逆转人乳腺癌细胞多药耐药表型

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The circumvention of multidrug resistance (MDR) plays a critically important role in the success of chemotherapy. The aimof thiswork is to investigate the effectiveness and possible mechanisms of the reversal ofMDR phenotype in human breast cancer cells by using doxorubicin-liposome-microbubble complexes (DLMC) assisted by ultrasound (US). DLMC is fabricated through conjugating doxorubicin (DOX)-liposome (DL) to the surface of microbubbles (MBs) via the biotin-avidin linkage. The resulting drug-loaded complexes are then characterized and incubated with MCF-7/ADR human breast cancer cells and followed by US exposure. Our results show the more rapid cellular uptake, evident enhancement of nuclear accumulation and less drug efflux in the resistant cells treated by DLMC + US than those treated by DL, DL + verapamil under the same US treatment or DLMC without US. The enhanced drug delivery and cellular uptake also associated with the increase of cytotoxicity against MCF-7/ADR cells, lower MCF-7/ADR cell viability and higher apoptotic cells. Mechanism investigations further disclose a significant increase of reactive oxygen species (ROS) level, enhanced DNA damage and obvious reduction of P-glycoprotein expression in the resistant cells treatedwith DLMC + US comparedwith the control cases of cells treated by DLMC, DL + US or DL + verapamil + US. In conclusion, our study demonstrates that DLMC in combination with US may provide an effective delivery of drug to sensitize cells to circumvent MDR and to enhance the therapeutic index of the chemotherapy.
机译:规避多药耐药性(MDR)在化学疗法的成功中起着至关重要的作用。这项工作的目的是通过使用超声辅助的阿霉素-脂质体-微泡复合物(DLMC)研究人乳腺癌细胞中MDR表型逆转的有效性和可能的​​机制。 DLMC是通过生物素-亲和素连接将阿霉素(DOX)-脂质体(DL)与微泡(MBs)结合而制成的。然后表征所得的载有药物的复合物,并与MCF-7 / ADR人乳腺癌细胞孵育,然后进行US暴露。我们的结果表明,与在相同的美国治疗或没有US的DLMC情况下,用DL,DL +维拉帕米治疗的耐药细胞相比,用DLMC + US治疗的耐药细胞具有更快的细胞摄取速度,明显的核积累增强和更少的药物外排。增强的药物传递和细胞摄取还与针对MCF-7 / ADR细胞的细胞毒性增加,MCF-7 / ADR细胞活力降低和凋亡细胞增多有关。机制研究进一步揭示了与用DLMC,DL + US或DL处理的对照细胞相比,用DLMC + US处理的抗性细胞中的活性氧(ROS)水平显着增加,DNA损伤增强和P-糖蛋白表达明显降低。 +维拉帕米+美国。总而言之,我们的研究表明DLMC与US结合可以有效地递送药物,从而使细胞对MDR敏感并增强化疗的治疗指数。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号